Fig. 4

Safety assessment of VNP-shCCDC25 in vivo. A The changing trend of body weight of mouse was monitored daily after treatments (n = 6). B The ratio of organ weight to body weight of mouse in different administration groups (n = 3). C The picture of spleen after administrations. D–G Serological analysis of ALT (D), AST (E), BUN (F), and Scr (G) in serum 5 days after treatments (n = 5). H H&E staining of organs in different administration groups. Scale bars: 200 μm. I–L Routine blood test after 5 days of treatment (n = 5). Data are shown as the mean ± SD. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns: no significance